The global peptide therapeutics market is projected to grow at a significant CAGR of around 9.0% during the forecast period. Peptides have gained a wide range of applications in medicine and biotechnology. In the last ?ve years (2015–2019), the US Food Drug Administration (FDA) has authorized a total of 208 new drugs, 15 of which were peptides or peptide-containing molecules, which account for 7% of the total number of drugs. The primary factor that drives the peptide therapeutics market growth includes the potent and specific, yet safe, mode of action of peptides.
Browse the full report description of "Global Peptide Therapeutics Market Size, Share & Trends Analysis Report by Route of Administration (Oral and Parenteral), by Application (Cancer, Gastrointestinal Disorders, Central Nervous System Disorders, Respiratory Disorders, and Others), Forecast 2020-2026" at https://www.omrglobal.com/industry-reports/peptide-therapeutics-market
Besides the increased prevalence of diseases such as cancer also drives the global peptide therapeutics industry growth during the forecast period. Increased rate of mortality due to cancer has led to an increase in emphasis on the advancements of the drugs and products to combat the situation, which fuels the growth for the global peptide therapeutics market over the forecast period.
Based on the route of the delivery segment of the market, oral held the key share in the market. Oral delivery is the preferred route of drug administration, as the majority of patients see it as the most convenient way to take their drugs. Drugs taken by the oral route have the highest level of patient compliance due to the ease and simplicity of taking medications. Despite a large number of protein therapeutics being discovered each year, oral delivery continues to be a barrier. As a whole, protein and peptide drugs have low bioavailability when administered orally due to problematic barriers including gastrointestinal proteases, the epithelial barrier, and efflux pumps.
Further, the presence of the key players that provides suitable and proper drugs also drives the growth of the peptide therapeutics market during the forecast period. Players such as Amgen Inc., Eli Lilly and Co., Pfizer, Inc., Bristol-Myer Squibb Co., AstraZeneca Plc, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck & Co. Inc., Novartis International AG, Novo Nordisk A/S, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceuticals Industries Ltd., and others are some of the key players contributing to the growth of the market.
Global Peptide Therapeutics Market – Segmentation
By Route of Administration
By Application
Global Peptide Therapeutics Market – Segmentation by Region
North America
Europe
Asia-Pacific
Rest of the World